Metrics as of 10/16/2026, 08:37 AM (Berlin time), refresh in progress.
TAO Synergies Inc.
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the…
1D
-8.0%
1W
-13.0%
1M
-9.7%
6M
-32.8%
YTD
-9.2%
1Y
-56.8%
2Y
–
5Y
–
10Y
–
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
~25% stronger price swings than usual
P/E
-0.84
P/B
1.44
EV/EBITDA
-2.84
RETURN ON EQUITY
-53.8%
NET MARGIN
-10,492.4%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
93.3%
FLOAT SHARES
7,319,733
AVG. DAILY VOLUME (30D)
222,573
TAO Synergies Inc. is a company in the Technology sector, Software - Application industry, headquartered in United States.
The CEO is Joshua N. Silverman, the company employs around 5 people.
The IPO was on 02/07/2025; the stock trades on NASDAQ under the ticker TAOX.
The next earnings date is 02/12/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
No, TAO Synergies currently does not pay a dividend.
Comparable stocks include Salesforce, ServiceNow, Uber Technologies, Snowflake, Automatic Data Processing, Datadog, Cadence Design Systems and Adobe.
Clicking "Analyze stock" lets five strategies assess TAO Synergies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.